Results 1 to 10 of about 655,147 (306)
Discovery and development of Factor Xa inhibitors (2015–2022) [PDF]
Frontiers in Pharmacology, 2023 As a pathological coagulation process, thrombus can lead to many serious diseases, including ischemic stroke, acute myocardial infarction (AMI), acute coronary syndrome (ACS), and deep venous thrombosis (DVT).
Wei Zheng +5 more
doaj +3 more sources
Theoretical Study of Molecular Structure and Physicochemical Properties of Novel Factor Xa Inhibitors and Dual Factor Xa and Factor IIa Inhibitors [PDF]
Molecules, 2016 The geometries and energies of factor Xa inhibitors edoxaban, eribaxaban, fidexaban, darexaban, letaxaban, and the dual factor Xa and thrombin inhibitors tanogitran and SAR107375 in both the gas-phase and aqueous solution were studied using the Becke3LYP/
Milan Remko, Anna Remková, Ria Broer
doaj +3 more sources
Direct factor Xa inhibitors and the risk of cancer and cancer mortality: A Danish population-based cohort study. [PDF]
PLoS MedicineBackgroundPreclinical animal studies have suggested that myeloid cell-synthesized coagulation factor X dampens antitumor immunity and that rivaroxaban, a direct factor Xa inhibitor, can be used to promote tumor immunity. This study was aimed at assessing
Floris Bosch +4 more
doaj +4 more sources
Swiss Medical Weekly, 2023 Anticoagulants are essential in preventing and treating thrombosis. Unfortunately, their use is accompanied by an enhanced risk of bleeding. Since the introduction of direct oral anticoagulants (DOACs), the risk of major bleeding has been reduced but ...
Anne Angelillo-Scherrer +5 more
doaj +2 more sources
Oral Direct Factor Xa Inhibitors [PDF]
Circulation Research, 2012 Vitamin K antagonists, such as warfarin, have been the mainstay of oral anticoagulation for many decades. Although effective, warfarin has numerous limitations, including a variable dose requirement from patient to patient because of differences in dietary vitamin K intake, common genetic polymorphisms, and multiple drug interactions that affect its ...
Calvin H. Yeh +2 more
openalex +3 more sources
Heavy menstrual bleeding on direct factor Xa inhibitors: Rationale and design of the MEDEA study [PDF]
Research and Practice in Thrombosis and Haemostasis, 2021 Background In premenopausal women, treatment with direct oral factor Xa inhibitors is associated with an increased risk of heavy menstrual bleeding (HMB) compared with vitamin K antagonists (VKA).
Eva N. Hamulyák +18 more
doaj +2 more sources
Nature Communications, 2017 A major drawback in the clinical use of the oral anticoagulants that directly inhibit factor Xa in order to prevent blood clot formation is the potential for life threatening bleeding events.
Daniël Verhoef +6 more
doaj +2 more sources
Reversing factor Xa inhibitors – clinical utility of andexanet alfa
Journal of Blood Medicine, 2017 Approximately half of patients started on an oral anticoagulant in the USA now receive one of the newer direct oral anticoagulants (DOACs). Although there is an approved reversal agent for the direct thrombin inhibitor dabigatran, a specific reversal ...
Scott Kaatz +5 more
openalex +3 more sources
Efficacy and Toxicity of Factor Xa Inhibitors
Journal of Pharmacy & Pharmaceutical Sciences, 2013 Venous thromboembolism (VTE) is a serious disease that is often neglected, and effective and safe antithrombotic treatments are a public health priority.
Maryna Bondarenko +4 more
doaj +5 more sources
Clinical and Applied Thrombosis/Hemostasis, 2019 Recombinant coagulation factor Xa (FXa), inactivated Zh-zo, also known as andexanet alfa (AA), is a modified version of human FXa that has been developed to neutralize FXa inhibitors.
Fakiha Siddiqui BDS +7 more
doaj +2 more sources